220 related articles for article (PubMed ID: 35853202)
21. Defective efferocytosis of vascular cells in heart disease.
Singh B; Li K; Cui K; Peng Q; Cowan DB; Wang DZ; Chen K; Chen H
Front Cardiovasc Med; 2022; 9():1031293. PubMed ID: 36247464
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis.
Yurdagul A; Doran AC; Cai B; Fredman G; Tabas IA
Front Cardiovasc Med; 2017; 4():86. PubMed ID: 29379788
[TBL] [Abstract][Full Text] [Related]
23. Immunoproteasome subunit β5i regulates diet-induced atherosclerosis through altering MERTK-mediated efferocytosis in Apoe knockout mice.
Liao J; Xie Y; Lin Q; Yang X; An X; Xia Y; Du J; Wang F; Li HH
J Pathol; 2020 Mar; 250(3):275-287. PubMed ID: 31758542
[TBL] [Abstract][Full Text] [Related]
24. Macrophage-specific deletion of MIC26 (APOO) mitigates advanced atherosclerosis by increasing efferocytosis.
Tang X; Huang Z; Wang F; Chen J; Qin D; Peng D; Yu B
Atherosclerosis; 2023 Dec; 386():117374. PubMed ID: 37995600
[TBL] [Abstract][Full Text] [Related]
25. 2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis.
Jarr KU; Kojima Y; Weissman IL; Leeper NJ
Arterioscler Thromb Vasc Biol; 2022 Jun; 42(6):e145-e154. PubMed ID: 35387480
[TBL] [Abstract][Full Text] [Related]
26. Macrophage Apoptosis and Necrotic Core Development in Atherosclerosis: A Rapidly Advancing Field with Clinical Relevance to Imaging and Therapy.
Gonzalez L; Trigatti BL
Can J Cardiol; 2017 Mar; 33(3):303-312. PubMed ID: 28232016
[TBL] [Abstract][Full Text] [Related]
27. Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis.
Marsch E; Theelen TL; Demandt JA; Jeurissen M; van Gink M; Verjans R; Janssen A; Cleutjens JP; Meex SJ; Donners MM; Haenen GR; Schalkwijk CG; Dubois LJ; Lambin P; Mallat Z; Gijbels MJ; Heemskerk JW; Fisher EA; Biessen EA; Janssen BJ; Daemen MJ; Sluimer JC
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2545-53. PubMed ID: 25256233
[TBL] [Abstract][Full Text] [Related]
28. Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis.
Kasikara C; Schilperoort M; Gerlach B; Xue C; Wang X; Zheng Z; Kuriakose G; Dorweiler B; Zhang H; Fredman G; Saleheen D; Reilly MP; Tabas I
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33630758
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of continual efferocytosis by macrophages and its role in mitigating atherosclerosis.
Kumar D; Pandit R; Yurdagul A
Immunometabolism (Cobham); 2023 Jan; 5(1):e00017. PubMed ID: 36710920
[TBL] [Abstract][Full Text] [Related]
30. Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets.
Galindo CL; Khan S; Zhang X; Yeh YS; Liu Z; Razani B
Expert Opin Ther Targets; 2023; 27(12):1231-1245. PubMed ID: 38009300
[TBL] [Abstract][Full Text] [Related]
31. CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis.
Doran AC; Ozcan L; Cai B; Zheng Z; Fredman G; Rymond CC; Dorweiler B; Sluimer JC; Hsieh J; Kuriakose G; Tall AR; Tabas I
J Clin Invest; 2017 Nov; 127(11):4075-4089. PubMed ID: 28972541
[TBL] [Abstract][Full Text] [Related]
32. Efferocytosis in atherosclerosis.
Adkar SS; Leeper NJ
Nat Rev Cardiol; 2024 May; ():. PubMed ID: 38750215
[TBL] [Abstract][Full Text] [Related]
33. Selective activation of CB2 receptor improves efferocytosis in cultured macrophages.
Jiang L; Chen Y; Huang X; Yuan A; Shao Q; Pu J; He B
Life Sci; 2016 Sep; 161():10-8. PubMed ID: 27474129
[TBL] [Abstract][Full Text] [Related]
34. Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits necrosis in atherosclerotic plaques.
Egaña-Gorroño L; Chinnasamy P; Casimiro I; Almonte VM; Parikh D; Oliveira-Paula GH; Jayakumar S; Law C; Riascos-Bernal DF; Sibinga NES
Atherosclerosis; 2019 Oct; 289():184-194. PubMed ID: 31439353
[TBL] [Abstract][Full Text] [Related]
35. The role of non-resolving inflammation in atherosclerosis.
Kasikara C; Doran AC; Cai B; Tabas I
J Clin Invest; 2018 Jul; 128(7):2713-2723. PubMed ID: 30108191
[TBL] [Abstract][Full Text] [Related]
36. Targeting mitochondrial function in macrophages: A novel treatment strategy for atherosclerotic cardiovascular disease?
Becker PH; Thérond P; Gaignard P
Pharmacol Ther; 2023 Jul; 247():108441. PubMed ID: 37201736
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT
Zhang Y; Wang Y; Zhou D; Zhang LS; Deng FX; Shu S; Wang LJ; Wu Y; Guo N; Zhou J; Yuan ZY
Am J Physiol Cell Physiol; 2019 Oct; 317(4):C776-C787. PubMed ID: 31390228
[TBL] [Abstract][Full Text] [Related]
38. Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation.
Rinne P; Guillamat-Prats R; Rami M; Bindila L; Ring L; Lyytikäinen LP; Raitoharju E; Oksala N; Lehtimäki T; Weber C; van der Vorst EPC; Steffens S
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2562-2575. PubMed ID: 30354245
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-21 Controls Circadian Regulation of Apoptosis in Atherosclerotic Lesions.
Schober A; Blay RM; Saboor Maleki S; Zahedi F; Winklmaier AE; Kakar MY; Baatsch IM; Zhu M; Geißler C; Fusco AE; Eberlein A; Li N; Megens RTA; Banafsche R; Kumbrink J; Weber C; Nazari-Jahantigh M
Circulation; 2021 Sep; 144(13):1059-1073. PubMed ID: 34233454
[TBL] [Abstract][Full Text] [Related]
40. Reduction of TMAO level enhances the stability of carotid atherosclerotic plaque through promoting macrophage M2 polarization and efferocytosis.
Shi W; Huang Y; Yang Z; Zhu L; Yu B
Biosci Rep; 2021 May; 41(6):. PubMed ID: 33969376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
